Legis Daily

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

USA116th CongressHR-2115| House 
| Updated: 10/29/2019
Abigail Davis Spanberger

Abigail Davis Spanberger

Democratic Representative

Virginia

Cosponsors (5)
Jefferson Van Drew (Republican)Van Taylor (Republican)Brendan F. Boyle (Democratic)Jodey C. Arrington (Republican)Elissa Slotkin (Democratic)

Ways and Means Committee, Finance Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements. The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 8, 2019
Introduced in House
Apr 8, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 8, 2019
Referred to the Subcommittee on Health.
Apr 9, 2019
Referred to the Subcommittee on Health.
May 21, 2019
Subcommittee Hearings Held.
Oct 28, 2019
Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.
Oct 28, 2019
Considered under suspension of the rules. (consideration: CR H8516-8519)
Oct 28, 2019
DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.
Oct 28, 2019
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Oct 28, 2019
Considered as unfinished business. (consideration: CR H8520-8521)
Oct 28, 2019
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
View Vote
Oct 28, 2019
Motion to reconsider laid on the table Agreed to without objection.
Oct 28, 2019
The title of the measure was amended. Agreed to without objection.
Oct 29, 2019
Received in the Senate and Read twice and referred to the Committee on Finance.
  • April 8, 2019
    Introduced in House


  • April 8, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 8, 2019
    Referred to the Subcommittee on Health.


  • April 9, 2019
    Referred to the Subcommittee on Health.


  • May 21, 2019
    Subcommittee Hearings Held.


  • October 28, 2019
    Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.


  • October 28, 2019
    Considered under suspension of the rules. (consideration: CR H8516-8519)


  • October 28, 2019
    DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.


  • October 28, 2019
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • October 28, 2019
    Considered as unfinished business. (consideration: CR H8520-8521)


  • October 28, 2019
    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
    View Vote


  • October 28, 2019
    Motion to reconsider laid on the table Agreed to without objection.


  • October 28, 2019
    The title of the measure was amended. Agreed to without objection.


  • October 29, 2019
    Received in the Senate and Read twice and referred to the Committee on Finance.

Health

Related Bills

  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • HR 116-3415: Real-Time Beneficiary Drug Cost Bill
  • S 116-3129: Lower Costs, More Cures Act of 2019
  • HR 116-2113: Prescription Drug STAR Act
  • HR 116-3408: Shop Rx Act of 2019
  • HR 116-19: Lower Costs, More Cures Act of 2019
Business recordsGovernment information and archivesHealth care costs and insuranceInflation and pricesPrescription drugsRetail and wholesale trades

Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

USA116th CongressHR-2115| House 
| Updated: 10/29/2019
Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to publish certain payment information regarding pharmacy benefit managers (PBMs) and prescription drugs. Specifically, the CMS must publish certain information, as reported by PBMs, relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies, in accordance with specified confidentiality requirements. The bill also provides statutory authority for certain provisions of the CMS rule titled "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses," published on May 23, 2019. The rule requires, in part, Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that is capable of integrating with at least one prescriber's electronic prescribing system or electronic health record. The tool must provide prescribers with patient-specific, real-time formulary and benefit information, including information regarding cost-sharing, formulary alternatives, and utilization management requirements. The rule takes effect January 1, 2021.

Bill Text Versions

View Text
3 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 8, 2019
Introduced in House
Apr 8, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 8, 2019
Referred to the Subcommittee on Health.
Apr 9, 2019
Referred to the Subcommittee on Health.
May 21, 2019
Subcommittee Hearings Held.
Oct 28, 2019
Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.
Oct 28, 2019
Considered under suspension of the rules. (consideration: CR H8516-8519)
Oct 28, 2019
DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.
Oct 28, 2019
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Oct 28, 2019
Considered as unfinished business. (consideration: CR H8520-8521)
Oct 28, 2019
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
View Vote
Oct 28, 2019
Motion to reconsider laid on the table Agreed to without objection.
Oct 28, 2019
The title of the measure was amended. Agreed to without objection.
Oct 29, 2019
Received in the Senate and Read twice and referred to the Committee on Finance.
  • April 8, 2019
    Introduced in House


  • April 8, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 8, 2019
    Referred to the Subcommittee on Health.


  • April 9, 2019
    Referred to the Subcommittee on Health.


  • May 21, 2019
    Subcommittee Hearings Held.


  • October 28, 2019
    Ms. Schakowsky moved to suspend the rules and pass the bill, as amended.


  • October 28, 2019
    Considered under suspension of the rules. (consideration: CR H8516-8519)


  • October 28, 2019
    DEBATE - The House proceeded with forty minutes of debate on H.R. 2115.


  • October 28, 2019
    At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.


  • October 28, 2019
    Considered as unfinished business. (consideration: CR H8520-8521)


  • October 28, 2019
    On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 403 - 0 (Roll no. 586). (text: CR H8516)
    View Vote


  • October 28, 2019
    Motion to reconsider laid on the table Agreed to without objection.


  • October 28, 2019
    The title of the measure was amended. Agreed to without objection.


  • October 29, 2019
    Received in the Senate and Read twice and referred to the Committee on Finance.
Abigail Davis Spanberger

Abigail Davis Spanberger

Democratic Representative

Virginia

Cosponsors (5)
Jefferson Van Drew (Republican)Van Taylor (Republican)Brendan F. Boyle (Democratic)Jodey C. Arrington (Republican)Elissa Slotkin (Democratic)

Ways and Means Committee, Finance Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • HR 116-2296: More Efficient Tools to Realize Information for Consumers Act
  • HR 116-3415: Real-Time Beneficiary Drug Cost Bill
  • S 116-3129: Lower Costs, More Cures Act of 2019
  • HR 116-2113: Prescription Drug STAR Act
  • HR 116-3408: Shop Rx Act of 2019
  • HR 116-19: Lower Costs, More Cures Act of 2019
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsGovernment information and archivesHealth care costs and insuranceInflation and pricesPrescription drugsRetail and wholesale trades